News: Synchronica Plc (DAU.L)

DAU.L on London Stock Exchange

2.88GBp
23 Dec 2009
Price Change (% chg)

-0.25p (-7.99%)
Prev Close
3.13p
Open
3.13p
Day's High
3.13p
Day's Low
2.60p
Volume
1,005,799
Avg. Vol
110,711
52-wk High
5.00p
52-wk Low
2.25p

view news for:
Select another date:

Wed, Nov 4 2009

STOCKS NEWS EUROPE-Synchronica up on first devices order

Shares in Synchronica rise 11 percent after the developer of mobile email software receives its first purchase order for low-cost mobile devices from a Central-African operator.

Continue Reading

STOCKS NEWS UK-Synchronica up on first devices order

STOCKS NEWS Reuters Results diary

STOCKS NEWS UK-Eros rises on strong Q2, proposed Indian IPO

STOCKS NEWS Reuters Results diary

STOCKS NEWS UK-Immunodiagnostic Systems up as H1 sales rise

STOCKS NEWS Reuters Results diary

STOCKS NEWS EUROPE-Synchronica up on contract win

Shares in Synchronica climb 6.7 percent as the AIM-listed mobile email and synchronisation provider announces a contract win in South-East Asia, which FinnCap describes as a "potentially lucrative" revenue share contract.

STOCKS NEWS UK-SThree down; H1 profit slumps, outlook tough

STOCKS NEWS Reuters Results diary

STOCKS NEWS EUROPE-Domino's Pizza jumps on FY upgrades

Shares in Domino's Pizza UK & IRL surge 9 percent to head the FTSE 250 gainers after Britain's biggest pizza delivery chain says it expects to exceed market expectations for the full-year after posting a 25 percent jump in first-half profit.

STOCKS NEWS UK-Domino's Pizza jumps on FY upgrades

STOCKS NEWS Reuters Results diary

STOCKS NEWS EUROPE-UK small caps gain 0.2 percent early

The FTSE Small Cap index gains 0.2 percent in early trade, underperforming both the blue chips and the midcaps , which add 0.8 percent and 0.7 percent, respectively.

PRESS DIGEST - British business press - April 28

GlaxoSmithKline unveiled the results of an 8,000 patient phase-III trial of its Avodart drug at an American Urological Association meeting in Chicago. The world's first preventative treatment for prostate cancer may be on the market in a year after the trial found the drug reduced at-risk patients' chances of developing the disease by nearly a quarter.

Select another date:

Market Views

» More DAU.L Market Views

Press Releases

view news for: